Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Taïdo Femiflor is an oral dietary supplement developed by Laboratoire des Réalisations Thérapeutiques ELERTE, specifically formulated to support vaginal health and maintain a balanced microbiota. The product contains a high concentration of the probiotic strain *Lactobacillus crispatus* (IP174178), which is a dominant and protective species in a healthy vaginal environment. The formulation is further enriched with Zinc and Vitamin B3 (Niacin). *Lactobacillus crispatus* helps prevent the overgrowth of pathogenic bacteria and yeast by maintaining an acidic pH and producing protective substances. Zinc and Vitamin B3 contribute to the maintenance of healthy mucous membranes and support the immune system's response to local infections. It is primarily indicated for women experiencing recurrent vaginal discomfort, such as vaginosis or mycosis, to help restore flora balance after treatment or during periods of hormonal change.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Taïdo Femiflor.